Petros Pharmaceuticals (PTPI) Stock Statistics & Valuation Metrics
Total Valuation
Petros Pharmaceuticals has a market cap or net worth of $118.22K. The enterprise value is -$4.17T.
- Market Cap
- $118.22K
- Enterprise Value
- -$4.17T
Share Statistics
Petros Pharmaceuticals has 42,372,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 42,372,260
- Owned by Insiders
- 33.82%
- Owned by Institutions
- ―
Financial Efficiency
Petros Pharmaceuticals’s return on equity (ROE) is 0.67 and return on invested capital (ROIC) is -161.67%.
- Return on Equity (ROE)
- 0.67
- Return on Assets (ROA)
- 0.37
- Return on Invested Capital (ROIC)
- -161.67%
- Return on Capital Employed (ROCE)
- -1.62
- Revenue Per Employee
- 0
- Profits Per Employee
- 637.87K
- Employee Count
- 3
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Petros Pharmaceuticals is 0.00. Petros Pharmaceuticals’s PEG ratio is 0.00.
- PE Ratio
- 0.00
- PS Ratio
- 0.00
- PB Ratio
- 0.21
- Price to FCF
- -0.04
- Price to Operating Cash Flow
- -0.04
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Petros Pharmaceuticals had revenue of 0 and earned 1.91M in profits. Earnings per share was -1.56.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -4.64M
- Pretax Income
- -4.50M
- Net Income
- 1.91M
- EBITDA
- -4.50M
- Earnings Per Share (EPS)
- -1.56
Cash Flow
In the last 12 months, operating cash flow was -3.72M and capital expenditures 0, giving a free cash flow of -3.72M billion.
- Operating Cash Flow
- -3.72M
- Free Cash Flow
- -3.72M
- Free Cash Flow per Share
- -0.08
Dividends & Yields
Petros Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2595.90%
- Earnings Yield
- -2000.07%
Stock Price Statistics
- Beta
- 1.18
- 52-Week Price Change
- -63.33%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Petros Pharmaceuticals upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Nov 14, 2023
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Petros Pharmaceuticals as a current ratio of 2.25, with Debt / Equity ratio of 0.00%
- Current Ratio
- 2.25
- Quick Ratio
- 2.25
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.14
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Petros Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Petros Pharmaceuticals EV to EBITDA ratio is 1.32, with an EV/FCF ratio of 0.90.
- EV to Sales
- 0.00
- EV to EBITDA
- 1.32
- EV to Free Cash Flow
- 0.90
- EV to Operating Cash Flow
- 0.90
Balance Sheet
Petros Pharmaceuticals has $3.49M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.49M billion.
- Cash & Marketable Securities
- $3.49M
- Total Debt
- $0.00
- Net Cash
- $3.49M
- Net Cash Per Share
- $0.08
- Tangible Book Value Per Share
- $0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Petros Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- 99.37%
